C
ContraFect
ContraFect Corporation (CFRX)
About ContraFect
ContraFect Corporation is a biotechnology company focused on developing innovative biologic therapies to combat life-threatening, drug-resistant infections. Operating in the healthcare and pharmaceutical market, ContraFect primarily serves hospitals, healthcare providers, and patients suffering from severe bacterial infections. The company's core products include lysins and direct lytic agents, which are designed to target and destroy antibiotic-resistant bacteria. ContraFect's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through product sales, partnerships, and licensing agreements. The company aims to address the growing global health crisis of antibiotic resistance by providing effective and novel treatment options.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- New York City, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CARB-X
Series A1 investor entered at this stage
Maxim Group LLC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ContraFect on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ContraFect on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.